Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus

NCT ID: NCT06057077

Last Updated: 2023-09-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-01
• Study Completion Date: 2024-12-31

Brief Summary

type 1 diabetes is an autoimmune disease and still, some unknown mechanisms are undiscovered millions of children and adults suffer from this type which need basal-bolus insulin as the classical regimen, and basal-bolus insulin is the best type of treatment is similar to the physiological pattern, so our target and may studies before how to preserve the residual beta cells or postpone the complete destruction or extend the honeymoon stage to improve quality of life, the most challenge at type 1 diabetes is diabetic ketoacidosis which affect the quality of life and risk of death so at our clinical trials using the combination of basal insulin-like degludec as its action extend to 72 hours and has high flexibility and less hypoglycemic events and has an affinity to 99% to albumin so may be considered the most type of insulin is similar to human physiological insulin as 50% of insulin pass through portal circulation so no insulin until now it is mimic the normal physiological insulin but IDeg is the nearest to normal until now, Objective: To compare the efficacy and safety of basal-bolus insulin degludec and semaglutide with regular standard of care versus basal-bolus insulin with regular standard of care in early type 1 diabetic patients.

In our study, the investigators will compare 2 groups of early type 1 patients in the age group 18 years to 35 years Protocol and Methodology for a Randomized Controlled Trial of Basal-Bolus Insulin Degludec and Semaglutide with Regular Standard of Care Versus Basal-Bolus Insulin with Regular Standard of Care in Early Type 1 Diabetic Patients

Study Design: Randomized, controlled, open-label trial

Setting: Outpatient diabetes clinics

Participants: Early type 1 diabetic patients (aged 18-35 years) who have been diagnosed with type 1 diabetes for less than 2 years and have a hemoglobin A1c (HbA1c) of 7.0-11%.

the tests will be done pre- and post :

1. Anti GAD 65 and anti IA2

2. HA1C

3. Serum C peptide

4. fasting insulin

5. serum zinc

Detailed Description

type 1 diabetes is an autoimmune disease and still, some unknown mechanisms are undiscovered millions of children and adults suffer from this type which need basal-bolus insulin as the classical regimen, and basal-bolus insulin is the best type of treatment is similar to the physiological pattern, so our target and may studies before how to preserve the residual beta cells or postpone the complete destruction or extend the honeymoon stage to improve quality of life, the most challenge at type 1 diabetes is diabetic ketoacidosis which affect the quality of life and risk of death so at our clinical trials using the combination of basal insulin-like degludec as its action extend to 72 hours and has high flexibility and less hypoglycemic events and has an affinity to 99% to albumin so may be considered the most type of insulin is similar to human physiological insulin as 50% of insulin pass through portal circulation one of the amazing advantages of IDeg is that no accumulation After 2-3 days of once-daily dosing, IDeg concentrations reach a steady state with no additional accumulation since, at that time, the daily-injected dose equals the daily-eliminated quantity of insulin when repeated equivalent doses are delivered at sufficient intervals.

the tests will be done pre- and post :

1. Anti GAD 65 and anti IA2

2. HA1C

3. Serum C peptide

4. fasting insulin

5. serum zinc

Insulin-bound insulin :

one other advantage of IDeg is insulin-bound insulin so no difference in clearance at renal or liver-impaired patients and normal functions. Albumin-bound insulins are not as easily filtered by the kidney as unbound insulins. Thus, hepatic and renal impairment have no effect on the PK characteristics of these insulin mimics.

synergism between semaglutide as GLP1 agonist and ultralong acting insulin like IDeg is suspected to give more benefits to early type 1 diabetes like extending the honeymoon phase and may preserve the residual beta cells function also may affect autoantibodies like anti-GAD65 and anti islets cells 2 anri IA2 In our study, the investigators will compare 2 groups of early type 1 patients in the age group 18 years to 35 years Protocol and Methodology for a Randomized Controlled Trial of Basal-Bolus Insulin Degludec and Semaglutide with Regular Standard of Care Versus Basal-Bolus Insulin with Regular Standard of Care in Early Type 1 Diabetic Patients

Objective: To compare the efficacy and safety of basal-bolus insulin degludec and semaglutide with regular standard of care versus basal-bolus insulin with regular standard of care in early type 1 diabetic patients.

Study Design: Randomized, controlled, open-label trial

Setting: Outpatient diabetes clinics

Participants: Early type 1 diabetic patients (aged 18-35 years) who have been diagnosed with type 1 diabetes for less than 2 years and have a hemoglobin A1c (HbA1c) of 7.0-11%.

Exclusion Criteria:

Pregnancy or breastfeeding History of severe hypoglycemia History of diabetic ketoacidosis History of pancreatitis History of hypersensitivity to insulin degludec or semaglutide Use of any other antidiabetic medications, other than basal-bolus insulin

Interventions:

Arm 1: Basal-bolus insulin degludec and semaglutide with regular standard of care Arm 2: Basal-bolus insulin with the regular standard of care

Regular standard of care:

Diabetes self-management education Nutritional counseling Physical activity counseling Self-monitoring of blood glucose (SMBG) Insulin dose adjustment Basal-bolus insulin degludec: Administered once daily Dosing adjusted based on SMBG results Semaglutide: Administered once weekly dosing adjusted based on SMBG results

Outcomes:

Primary outcome: Change in HbA1c from baseline to 24 weeks

Secondary outcomes:

Change in body weight from baseline to 24 weeks Frequency of hypoglycemia episodes from baseline to 24 weeks Time in range (TIR) from baseline to 24 weeks Quality of life from baseline to 24 weeks

Sample Size:

A sample size of 120 participants (60 per arm) is estimated to be sufficient to detect a difference of 0.5% in HbA1c between the two arms with a power of 80% and a significance level of 0.05.

Randomization:

Participants will be randomized to one of the two arms using a computer-generated random number table.

Blinding:

The study is open-label, meaning that participants and investigators will be aware of which treatment arm they are in.

Follow-up:

Participants will be followed for 24 weeks. They will be required to attend clinic visits every 6 weeks for assessments of HbA1c, body weight, and frequency of hypoglycemia episodes. They will also be required to wear a continuous glucose monitor (CGM) for 1 week at baseline and at 24 weeks to assess TIR.

Data Analysis:

Data will be analyzed using SPSS software. The primary outcome will be analyzed using an unpaired t-test. Secondary outcomes will be analyzed using appropriate statistical tests, such as chi-squared tests and ANOVA.

Safety:

All participants will be monitored closely for any adverse events. Any adverse events will be reported to the study's safety monitoring committee.

Ethical Considerations:

The study will be conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. The study protocol will be reviewed and approved by an institutional review board.

Informed Consent:

All participants will be required to provide written informed consent before participating in the study.

Discussion:

This randomized controlled trial will compare the efficacy and safety of basal-bolus insulin degludec and semaglutide with the regular standard of care versus basal-bolus insulin with the regular standard of care in early type 1 diabetic patients. The results of this study will provide valuable information about the best treatment options for this population.

Conditions

Type 1 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

60 early type 1 diabetes with semaglutide and degludec basal bolus insulin

degludec administered once daily bolus insulin three times daily and time in range and Semaglutide once weekly

Group Type: ACTIVE_COMPARATOR

Semaglutide weekly injection

Intervention Type: DRUG

semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity

60 early type 1 diabetes with degludec basal bolus insulin with regular standard of care

60 patients' Basal insulin degludec administered once daily according to the SMBG and continuous plan at the clinic bolus insulin three times daily according to the meals and time in range and carbohydrate index Dosing adjusted based on SMBG results

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Semaglutide weekly injection

semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity

Intervention Type: DRUG

Other Intervention Names

tresiba once daily

Eligibility Criteria

Inclusion Criteria

early diagnosed type 1 diabetic patients were diagnosed in the last 6 months age of two groups: from 18-35 years basal-bolus insulin patients

Exclusion Criteria

no oral hypoglycemic drugs no pregnancy no hypoglycemic drugs or immunosuppressant no history of diabetic ketoacidosis

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ministry of Health, Saudi Arabia

OTHER_GOV

Sponsor Role: lead

Responsible Party

Amr kamel khalil Ahmed

public health department, MSc, Riaydh first health cluster, Ministry of health , Saudia arabia

Responsibility Role: PRINCIPAL_INVESTIGATOR

References

Ang JE, Pandher R, Ang JC, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Baird RD, Friedman L, Derynck M, Vanhaesebroeck B, Eccles SA, Kaye SB, Workman P, de Bono JS, Raynaud FI. Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Mol Cancer Ther. 2016 Jun;15(6):1412-24. doi: 10.1158/1535-7163.MCT-15-0815. Epub 2016 Apr 5.

Reference Type: RESULT

PMID: 27048952 (View on PubMed)

Ahmed A, Monir Akl M. Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression. Adv Pharm Bull. 2024 Jul;14(2):262-265. doi: 10.34172/apb.2024.040. Epub 2024 Mar 18.

Reference Type: DERIVED

PMID: 39206389 (View on PubMed)

Other Identifiers

Amr Ahmed, Maher M.Akl

Identifier Type: -

Identifier Source: org_study_id